VBIO - Vitality Biopharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5100
-0.0300 (-5.56%)
At close: 3:51PM EST
Stock chart is not supported by your current browser
Previous Close0.5400
Open0.5050
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.5050 - 0.5500
52 Week Range0.0400 - 6.0000
Volume18,999
Avg. Volume39,903
Market Cap27.147M
Beta (3Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.40
Trade prices are not sourced from all markets
  • GlobeNewswire29 days ago

    Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board

    LOS ANGELES, Jan. 24, 2019 -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of.

  • ACCESSWIRE4 months ago

    SeeThruEquity Issues Update on Vitality Biopharma (VBIO) with Target Price of $3.50

    NEW YORK, NY / ACCESSWIRE / November 7, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Vitality Biopharma, Inc. (VBIO) with a Target Price of $3.50. Vitality Biopharma, Inc. (OTCQB: VBIO, ''Vitality'') is focused on the development of cannabinoids for the treatment of serious neurological and inflammatory disorders, as well as pain and opioid addiction. Vitality's development pipeline is focused on a new class of cannabinoid prodrug pharmaceuticals called cannabosides.

  • ACCESSWIRE4 months ago

    Vitality Biopharma Tackling the Medical Benefits of Cannabis with a Diverse Pipeline

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vitality Biopharma, Inc. (VBIO), a cure development company, dedicated to unlocking the power of cannabinoid "prodrugs" as a means to treat serious neurological and inflammatory disorders.

  • ACCESSWIRElast year

    The Story Behind Growth: New Report Discusses Vitality Biopharma and Growlife - Emerging Trends Within New Industry

    NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Vitality Biopharma, Inc. ( OTCQB: VBIO ) and Growlife, Inc. ( ...